Study Shows that Drug Combination Therapies Effective in Treating Schwannomas and Meningiomas
The Synodos for NF2 consortium of the Children’s Tumor Foundation (CTF) today published its first set of results and released its second set of data in the leading scientific journal PLOS ONE.
The Children’s Tumor Foundation (CTF), the largest non-governmental funder of neurofibromatosis (NF) research, and PLOS ONE, a leading peer-reviewed scientific journal, are pleased to announce the successful completion of the first funding cycle of the Drug Discovery Initiative Registered Report (DDIRR) 2017 Awards, a funder-publisher partnership integrating the Registered Reports model into the grant application process.
The Children’s Tumor Foundation (CTF) invites all researchers to apply for a Clinical Research Award of up to $150,000 for projects involving manifestation(s) of any form of neurofibromatosis (NF). Pre-applications (Letters of Intent) are welcomed from June 4 to September 10, 2018.
By Salvatore La Rosa, VP Research and Development
Early investments from the Children’s Tumor Foundation are paying off and delivering innovative and impactful research. It’s great to see research moving forward thanks to the support of both private and public funding. Our philosophy of betting on high-risk high-reward projects is proving successful and will eventually help us realize our vision of ending NF.
The Vilcek Foundation is currently seeking applicants for the 2019 Vilcek Prizes for Creative Promise in Biomedical Science. We are accepting applications from foreign-born scientists age 38 and under from now through June 11, 2018. Three winners will each receive a $50,000 unrestricted cash prize and will be honored at an awards ceremony in New York City in April 2019.